BioGend Therapeutics Co., Ltd. (6733.TWO)
TWD 33.0
(-0.6%)
TWD 33.0
(-0.6%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -138.72 Million | -168.78 Million | -136.79 Million | -117.12 Million | - |
| Net Income | -169.22 Million | -213.89 Million | -144.26 Million | -145.59 Million | - |
| Depreciation & Amortization | 55.01 Million | 53.18 Million | 28.19 Million | 19.19 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -13.97 Million | -8.25 Million | -5.34 Million | -5.09 Million | - |
| Other non-cash items | -17.83 Million | -4.5 Million | -3.3 Million | -2.34 Million | - |
| Investing Cash Flow | -89.63 Million | 201.7 Million | -134.27 Million | -113.51 Million | - |
| Investments in PPE | -26.03 Million | -18.17 Million | -673 Thousand | -204 Thousand | - |
| Acquisitions | - | - | 26.4 Million | - | -11.46 Million |
| Investment purchases | -64 Million | - | -159.97 Million | -112.99 Million | - |
| Sales/Maturities of investments | - | 223.2 Million | - | -112.99 Million | - |
| Other Investing Activities | 79 Thousand | -3.32 Million | -39 Thousand | -316 Thousand | - |
| Financing Cash Flow | 396.41 Million | -4.81 Million | 287.84 Million | 260.9 Million | - |
| Debt repayment | -3.58 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 400 Million | - | 289.62 Million | 260 Million | - |
| Other Financing Activities | -3.58 Million | - | - | 903 Thousand | - |
| Accounts receivables | -15.42 Million | - | - | - | - |
| Accounts payables | 77 Thousand | - | - | - | - |
| Inventory | -11.64 Million | 4.13 Million | 1.37 Million | -7.9 Million | - |
| Other working capital | 13.09 Million | - | - | - | - |
| Cash at beginning of period | 163.64 Million | 136.32 Million | 120.03 Million | 89.77 Million | - |
| Cash at end of period | 330.51 Million | 163.64 Million | 136.32 Million | 120.03 Million | - |
| Capital Expenditure | -26.03 Million | -18.17 Million | -673 Thousand | -204 Thousand | - |
| Effect of forex changes on cash | -1.19 Million | -788 Thousand | -492 Thousand | - | - |
| Net cash flow / Change in cash | 166.86 Million | 27.32 Million | 16.28 Million | 30.26 Million | - |
| Free Cash Flow | -164.75 Million | -186.95 Million | -137.47 Million | -117.33 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -40.8 Million | -17.43 Million | -169.22 Million | -39.76 Million | -47.87 Million | -24.24 Million |
| Depreciation & Amortization | 13.31 Million | 13.03 Million | 55.01 Million | 13.83 Million | 13.84 Million | 13.75 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -1.32 Million | -32.07 Million | -13.97 Million | 17.28 Million | -7.57 Million | -3 Million |
| Other non-cash items | -2.16 Million | -1.25 Million | -17.83 Million | -13.08 Million | -2.3 Million | -1.7 Million |
| Investing Cash Flow | -346.52 Million | 239.05 Million | -89.63 Million | -10.35 Million | 35.19 Million | -97.87 Million |
| Investments in PPE | - | -90 Thousand | -26.03 Million | -7.85 Million | -504 Thousand | -1.08 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -106.24 Million | - | -64 Million | - | -64 Million | - |
| Sales/Maturities of investments | -239.76 Million | 239.76 Million | - | - | 100 Million | -100 Million |
| Other Investing Activities | -525 Thousand | -619 Thousand | 79 Thousand | -2.82 Million | -298 Thousand | 3.2 Million |
| Financing Cash Flow | -906 Thousand | -903 Thousand | 396.41 Million | -900 Thousand | -897 Thousand | -893 Thousand |
| Debt repayment | -906 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 400 Million | - | - | - |
| Other Financing Activities | -906 Thousand | - | - | - | - | - |
| Accounts receivables | -1.44 Million | - | - | - | - | - |
| Accounts payables | 1 Million | - | - | - | - | - |
| Inventory | -489 Thousand | 738 Thousand | -11.64 Million | -1.65 Million | 1.39 Million | -4.28 Million |
| Other working capital | 2.1 Million | - | - | - | - | - |
| Cash at beginning of period | 531.8 Million | 330.51 Million | 163.64 Million | 357.04 Million | 364.25 Million | 481.52 Million |
| Cash at end of period | 155.67 Million | 531.8 Million | 330.51 Million | 330.51 Million | 357.04 Million | 364.25 Million |
| Capital Expenditure | - | -90 Thousand | -26.03 Million | -7.85 Million | -504 Thousand | -1.08 Million |
| Effect of forex changes on cash | -96 Thousand | -856 Thousand | -1.19 Million | 5.24 Million | -1.36 Million | -4.89 Million |
| Net cash flow / Change in cash | -376.13 Million | 201.29 Million | 166.86 Million | -26.53 Million | -7.2 Million | -117.27 Million |
| Free Cash Flow | -28.6 Million | -36.08 Million | -164.75 Million | -28.38 Million | -40.65 Million | -14.69 Million |
GKOS
SONN
600523
HLG
RKDL
0LFS